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Abstract——Catecholamine neurotransmission plays a
key role in regulating a variety of behavioral and physio-
logic processes, and its dysregulation is implicated in both
neurodegenerative and neuropsychiatric disorders. Over
the last fourdecades, invivo electrochemistryhas enabled
the discovery of contrasting catecholamine regulation in
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An erratum has been published:
the brain. These rapid and spatially resolved measure-
ments have been conducted in brain slices, and in anes-
thetized and freely behaving animals. In this review, we
describe the methods enabling in vivo measurements of
dopamine and norepinephrine, and subsequent findings
regarding their release and regulation in intact animals.
We thereafter discuss key studies in awake animals,
demonstrating that these catecholamines are not only
differentially regulated, but are released in opposition of
each other during appetitive and aversive stimuli.
I. Introduction
The catecholamine neurotransmitters dopamine and nor-
epinephrinemodulate avariety of behavioral andphysiologic
processes through their actions on postsynaptic receptors,
and their dysregulation underlies the pathophysiology of
many disease states. Deficits in dopamine and norepineph-
rine are a hallmark of neurodegenerative disorders such as
Alzheimer’s (Weinshenker, 2008) and Parkinson’s disease
(Schapira, 2009), andadaptations in catecholamine signaling
are thought to contribute to the development of psychiatric
disorders such as depression and drug addiction (Koob and
Volkow, 2010; Chaudhury et al., 2015). Despitemaking up a
relatively small proportion of synapses (Brady et al., 2005),
catecholamine neurons can signal through volume trans-
mission (Garris etal., 1994;Craggetal., 2001) toaffectawide
variety of downstream targets and influence communication
throughout the entire brain. Over 40 years ago, Ralph
Adams envisioned using electrochemistry in vivo tomeasure
oxidizable neurotransmitters (Kissinger et al., 1973). This
technique has enabled researchers tomeasure neurotrans-
mitter release anduptake in brain slices, anesthetized, and
freely behaving animals to more precisely determine their
actions on neural communication and behavior. Although
several electrochemical techniques have been applied to
the challenge, fast-scan cyclic voltammetry (FSCV) has
been more widely applied due to its fast time resolution
and chemical selectivity over other measurements.
It is impossible to cover the last four decades of in vivo
electrochemistry in a single review. Therefore, this re-
view has three goals. First, we will provide a general
overview of FSCV and the pioneering work in brain slices
that led to measurements in intact animals. Second, we
will focus on the use of anesthetized animals combined
with pharmacology to reveal differences in regulation of
dopamine and norepinephrine. Third, we will highlight
studies in freely moving animals that reveal contrasting
roles for these catecholamines in modulating behavior.
II. Building the Foundation for
In Vivo Recordings
A. Electrochemical Methods for
Catecholamine Measurements
Electrochemical methods have enabled researchers
to measure dynamic fluctuations of catecholamines in
brain tissue (Robinson et al., 2008). These methods rely
on the oxidation or reduction of the molecule of interest
at a solid electrode, and the resultant current provides a
quantitative measure of catecholamine concentrations.
Electrochemical measurements have a time resolution
sufficient to study both release and uptake, and can be
combined with pharmacology to probe local mecha-
nisms governing extracellular neurotransmitter con-
centrations. The twomost commonly employedmethods
are FSCV and constant-potential amperometry.
In FSCV, a potential sweep is applied to an electrode
at a rapid scan rate (100–1000 V/s) to oxidize and reduce
electroactive species. The current from this potential
sweep results in a characteristic cyclic voltammogram
(Fig. 1) and can be converted into concentration esti-
mates for the species of interest with in vitro calibration
factors and multivariate analysis techniques (Keithley
et al., 2009; Rodeberg et al., 2015). FSCVmeasurements
are typically conducted at glass-encased, carbon-fiber
microelectrodes in which the sensor is 5–10 mm in
diameter, and with an active length of 50–150 mm.
The small size of the sensor allows for minimal tissue
damage, as well as excellent spatial selectivity (Peters
et al., 2004). Voltammetric measurements are typically
conducted at fast sampling frequencies by repeating the
potential sweep every 20–200 ms, allowing for the
detection of single release and uptake events.
Constant-potential amperometry (CPA) measure-
ments are also conducted at carbon-fiber microelec-
trodes; however, this method differs from FSCV in that
it uses a single potential to oxidize or reduce the
molecule of interest. The simplicity of this approach
results in better time resolution than FSCV because it
is only limited by the sampling frequency. Similar
to CPA, carbon-fiber microelectrodes are used in chro-
noamperometry, which also relies on a single electrol-
ysis potential. However, chronoamperometry differs
from CPA in that the potential is stepped periodically
instead of constantly applied. It is important to note
that in both CPA and chronoamperometry, any mole-
cule that is electroactive at that given potential will be
detected at the electrode. Thus, amperometric measure-
ments have poor chemical selectivity as compared with
FSCV. To combat this, researchers have turned to chem-
ically treated electrodes to enhance analyte selectivity
ABBREVIATIONS: BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; CPA, constant-potential amperometry; CRF,
corticotropin-releasing factor; DAT, dopamine transporter; FSCV, fast-scan cyclic voltammetry; GRK2, G protein–coupled receptor kinase 2;
ICSS, intracranial self-stimulation; LC, locus coeruleus; L-DOPA, levodopa; MFB, medial forebrain bundle; NAc, nucleus accumbens; nAChR,
nicotinic acetylcholine receptor; NET, norepinephrine transporter; NMDAR, N-methyl-D-aspartate receptor; NO, nitric oxide; OCT, organic
cation transporter; OT, olfactory tubercle; PFC, prefrontal cortex; PPTg, pedunculopontine tegmental nucleus; SD, Sprague-Dawley; SN,
substantia nigra; UBE3A, ubiquitin ligase E3A; vBNST, ventral BNST; VTA, ventral tegmental area; WKY, Wistar-Kyoto.
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(Gerhardt et al., 1984). For a detailed comparison of FSCV,
chronoamperometry, and CPA, we refer the reader to a
recent review (Bucher and Wightman, 2015).
In addition to electrochemical detection of endoge-
nous catecholamine release, catecholamines can also be
exogenously applied to examine the kinetics of neuro-
transmitter clearance. This approach has been used in
brain slices (Falkenburger et al., 2001), as well as in
anesthetized (Cass et al., 1992; Zahniser et al., 1999)
and freelymoving animals (Gerhardt et al., 1999; Sabeti
et al., 2002). Exogenous application is often used in
amperometric methods because it confirms the identity
of the measured species. However, the disappearance of
applied catecholamines reflects information about the
diffusion of the analyte away from the electrode surface,
as well as clearance due to uptake. Therefore, care must
be taken when interpreting data obtained by this
methodology.
Due to the chemical selectivity of FSCV over amper-
ometry, FSCV has been themore widely applied electro-
chemical technique for measuring both release and
uptake of catecholamines. A commonly used voltam-
metric waveform for detection of catecholamines sweeps
from 20.4 to +1.3 V at 400 V/s, applied every 100 ms
(Fig. 1). However, it is important to note that dopamine
and norepinephrine differ structurally by a single
hydroxyl group, and current voltammetric waveforms
cannot distinguish between cyclic voltammograms of
the two catecholamines in vivo. Thus, we and others
have turned to a histologic and pharmacological signal
validation method that is discussed further in Pharma-
cological Validation. Although this method ensures the
catecholamine signal is purely dopamine or norepineph-
rine, it typically precludes measurements in regions
containing mixed catecholamines, such as the prefron-
tal cortex. However, recent advances in optogenetics
(Deisseroth, 2015) and chemogenetics (Roth, 2016)
allow for the excitation or inhibition of specific cell
populations. Although dopamine and norepinephrine
cannot be differentiated electrochemically, it is possible
that these selective stimulation methods will further
extend the reach of FSCV for catecholamine measure-
ments throughout the brain. For the time being, the
electrochemical signal needs to be validated pharmaco-
logically to claim that the measured current is solely
dopaminergic or noradrenergic in nature.
B. Regulation of Extracellular Catecholamines in
Brain Slices
1. Release. In brain slice recordings, a carbon-fiber
electrode is positioned ;100 mm into the tissue near a
stimulating electrode. The release and subsequent up-
take of neurotransmitters are measured while directly
depolarizing nearby terminals (Kelly and Wightman,
Fig. 1. FSCV for the detection of catecholamines. The most commonly used waveform sweeps from 20.4 to +1.3 V at a scan rate of 400 V/s. The
positive-going scan oxidizes dopamine and norepinephrine to their ortho-quinone form, and the negative-going scan reduces them back to dopamine or
norepinephrine. Plotting the resultant current versus potential results in identical characteristic cyclic voltammograms (CVs) for both dopamine and
norepinephrine.
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1987; Palij et al., 1990). Early studies focused on
dopamine, and FSCV in brain slices allowed researchers
to determine that extracellular concentrations were a
balance of release anduptake,withmetabolismoperating
on a slower time scale (Near et al., 1988; Sulzer et al.,
2016). Dopamine release per stimulation pulse ranges
from ;15 nM in the basolateral amygdala to ;90 nM in
the dorsal striatum (Garris andWightman, 1994a, 1995).
These values are in stark contrast to norepinephrine
release, which reaches only ;2 nM in the dorsal lateral
geniculate, and ;7 nM in the anteroventral thalamus
(Mitchell et al., 1994; Garris and Wightman, 1995).
Additionally, maximal norepinephrine efflux only weakly
depends on stimulation current above 250 mA, unlike
striatal dopamine, which does not approach saturation
evenwith stimulation currents of 450mA (Kennedy et al.,
1992; Miles et al., 2002). Longer pulse trains are required
to elicit norepinephrine release in slices containing the
bed nucleus of the stria terminalis (BNST), and the
kinetics of norepinephrine release are slower as com-
pared with dopamine (Kennedy et al., 1992; Miles et al.,
2002). These differential release profiles may be due to
the differences in vesicular release rate between norepi-
nephrine and dopamine (Chiti and Teschemacher, 2007),
or differential dependence on N-type calcium channel
activity (Mitchell and Adams, 1993). Despite evidence
that both catecholamines are released from similar sized
vesicles (Bergquist and Ludwig, 2008; Papke et al., 2012),
themechanism underlying differential release kinetics in
slices is unknown.
2. Uptake. After catecholamines are released, they
are cleared from the extracellular space by neuronal
transporters. The rate of uptake is often approximated
using t1/2, the time it takes to clear half of the
neurotransmitter concentration from the extracellular
space. As measured by t1/2, uptake rates differ vastly
between dopamine and norepinephrine. For dopamine,
t1/2 values are ,0.1 second in both dorsal and ventral
striatum; for norepinephrine t1/2 values exceed 1.0
second (Garris and Wightman, 1994a, 1995; Mitchell
et al., 1994).
The primary clearance mechanism for dopamine is
mediated by the dopamine transporter (DAT), which
obeys Michaelis–Menten kinetics (Wightman et al.,
1988). Uptake rates are heterogeneous in subregions
of the striatum (Trout and Kruk, 1992; Jones et al.,
1996; Siciliano et al., 2014; Salinas et al., 2016), which
might be attributed to differences in striosome and
matrix compartments (Salinas et al., 2016). Researchers
have manipulated DAT expression to determine its con-
tribution to extracellular dopamine concentrations in
brain slice preparations, and genetic deletion of DAT
prolongs the life of extracellular striatal dopamine by
300-fold (Jones et al., 1998). Conversely, overexpression
of DAT results in a 50% faster dopamine uptake rate,
and an overall reduction in evoked dopamine concentra-
tions (Salahpour et al., 2008).
The primary clearance mechanism for norepineph-
rine is the norepinephrine transporter (NET), but
non-NET mechanisms may play a larger role in norepi-
nephrine clearance. The lifetime of ventral BNST
(vBNST) norepinephrine clearance is only prolonged
sixfold in NET knockout mice (Xu et al., 2000; Miles
et al., 2002), and both organic cation transporters (OCTs)
and DAT are expressed in the vBNST (Miles et al., 2002;
Gasser et al., 2009). Although DAT has a higher affinity
for dopamine over norepinephrine, DAT knockout mice
exhibit a slight reduction in vBNST norepinephrine
clearance rate (Miles et al., 2002). However, DAT is not
likely a major contributor to norepinephrine clearance in
animals with normal NET function because pharma-
cological blockade of DAT in rats does not affect norepi-
nephrine clearance rate in the vBNST (Palij and
Stamford, 1992). However, in cases of prolonged signal-
ing, DAT or OCTsmay serve as an additional mechanism
for norepinephrine clearance.
Although the main substrates for DAT and NET are
dopamine and norepinephrine, respectively, the role of
catecholamine transporters is further complicated in
regions receiving both dopaminergic and noradrenergic
innervation. Catecholamine transporters are notori-
ously promiscuous (Daws, 2009), and NET serves as
the primary clearance mechanism for both dopamine
and norepinephrine in the cortex (Moron et al., 2002).
Thus, care must be taken when choosing pharmacolog-
ical agents for signal validation, as discussed below in
Pharmacological Validation.
3. Autoreceptors. Extracellular catecholamine con-
centrations are also governed by autoreceptor control of
release. Circuitry is mostly severed in a slice prepara-
tion, which serves as an advantage when examining
regulation of release at catecholamine terminals. Any
effects on release exerted by receptor agonists/antagonists
can thus be attributed to direct actions on terminals.
The principal autoreceptor for dopamine is the D2
(Beaulieu and Gainetdinov, 2011). D2 receptors maxi-
mally inhibit dopamine release within 500–1000 ms,
and the time course varies between dorsal and ventral
striatum (Phillips et al., 2002). D2 receptors become
markedly desensitized after knockout of DAT due to
persistent elevation of extracellular dopamine concen-
trations (Jones et al., 1999). The principal autoreceptor
controlling norepinephrine efflux is the a2, and it
operates on a similar time course as D2 receptors (Palij
and Stamford, 1993; Trendelenburg et al., 2001). De-
spite having similar mechanisms in place to control
extracellular concentrations, the fundamental differ-
ences in dopamine and norepinephrine release and
uptake position them to influence neuronal communi-
cation in diverse ways.
C. Catecholaminergic Plasticity
Anumber of studies have used brain slice preparations to
investigate adaptations to release and uptake mechanisms.
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For example, self-administration of psychostimulants pro-
duces variable adaptations in dopamine regulation. Fol-
lowing 5 days of amphetamine self-administration, evoked
dopamine release is increased in brain slices containing
the nucleus accumbens (NAc) and is accompanied by
decreased D2 autoreceptor function (Calipari et al.,
2014b). Following cocaine self-administration, electri-
cally stimulated dopamine release is instead attenuated
in brain slices, and cocaine is less effective at elevating
dopamine concentrations (Mateo et al., 2005; Ferris et al.,
2011, 2012; Calipari et al., 2014a). However, when
cocaine self-administering animals are given a single
infusion of amphetamine, dopamine terminal function in
slices is restored; that is, evoked release magnitudes and
cocaine inhibition of DAT more closely resemble that of
drug-naive animals (Ferris et al., 2015). Interestingly,
increasing surface DAT density increases the potency of
the psychostimulants amphetamine and methamphet-
amine, without altering the effect of uptake blockers such
as cocaine (Salahpour et al., 2008; Calipari et al., 2013,
2015). DAT-overexpressing animals have faster uptake
rates, exhibit a threefold increase in amphetamine-
potentiated dopamine release as compared with controls,
and develop a preference for amphetamine at lower doses
as compared with wild-type animals (Salahpour et al.,
2008). Similar to DAT overexpression, animals that self-
administer methylphenidate have increased dopamine
uptake rates, and amphetamine and methamphetamine
potency is increased in these animals; that is, the
psychostimulants become more effective at inhibiting
dopamine uptake (Calipari et al., 2013).However, neither
methylphenidate self-administration nor DAT overex-
pression alters uptake inhibition by uptake blockers
cocaine and nomifensine (Calipari et al., 2013, 2015). In
addition, the potency of amphetamine differs between
striatal subregions, and is closely linked with uptake
rates; that is, elevated uptake rates are associated with
increased uptake inhibition by amphetamine (Siciliano
et al., 2014). Although both cocaine and amphetamine act
at DAT, it is clear from these functional measurements
that the potency of amphetamine, but not cocaine, is
dependent on DAT expression levels.
Catecholamine receptors are also regulated by G
protein–coupled receptor kinases, and deletion of G
protein–coupled receptor kinase 2 (GRK2) from D1- or
D2-containing neurons produces contrasting effects on
dopamine regulation in brain slices (Daigle et al., 2014).
GRK2 deletion in D1-containing neurons enhances
evoked dopamine release and uptake rates. Conversely,
GRK2 deletion in D2-containing neurons enhances D2
autoreceptor activity and depresses baseline dopamine
release without changing dopamine uptake rate (Daigle
et al., 2014). These adaptations are paralleled by
bidirectional sensitivity to cocaine: in D1-containing
neurons, GRK2 deletion enhances cocaine-amplified
dopamine release without altering cocaine-mediated
uptake inhibition. Conversely, lack of GRK2 in D2
neurons reduces cocaine-amplified dopamine release
and cocaine-mediated inhibition of uptake rates and is
accompanied by reduced behavioral sensitivity to a
cocaine challenge (Daigle et al., 2014). This hypodopa-
minergic state is similar to that of animals with a
history of cocaine self-administration (Mateo et al.,
2005; Ferris et al., 2011, 2012; Calipari et al., 2014a ).
Indeed, chronic cocaine administration reduces GRK2
expression in theNAc (Schroeder et al., 2009). Together,
these findings suggest that GRK2 expression in D2-
containing neurons is important for cocaine-mediated
dopamine release and uptake inhibition.
Brain slices have also been used to uncover changes to
dopamine regulation in rats reared in social isolation.
These animals exhibit enhanced dopamine release and
uptake as compared with group-reared rats (Yorgason
et al., 2016). Interestingly, social isolation amplifies
methamphetamine, but not cocaine inhibition of DAT
(Yorgason et al., 2016). Becausemethamphetamine and
cocaine both act at DAT, these findings suggest other
adaptations may play a role in the plasticity. The stress
of social isolation most likely facilitates release of
corticosterone, which has a profound impact on other
transport mechanisms, such as OCTs (Gasser et al.,
2006). In agreement with this hypothesis, corticoste-
rone decreases dopamine clearance in the NAc, pre-
sumably by inhibiting OCTs expressed in the NAc (Graf
et al., 2013).
Although fewer studies have used slice voltammetry
to assay changes in noradrenergic function, work from
the Stamford laboratory demonstrated adaptations in
somatodendritic norepinephrine release in the locus
coeruleus (LC). Bath application of the analgesic tra-
madol reduces norepinephrine clearance in slices
(Halfpenny et al., 1999), but chronic treatment does
not affect uptake mechanisms. Instead, chronic trama-
dol appears to sensitize a2 function, and in a manner that
resembles the actions of an antidepressant (Hopwood
et al., 2001). Although tramadol is an opioid analgesic,
these functional measurements of its pharmacological
effects lend support to its antidepressant activity in
mice (Rojas-Corrales et al., 1998). In another study,
researchers asked how presynaptic norepinephrine reg-
ulation is changed inmice lacking themetabolic enzyme
monoamine oxidase A. In monoamine oxidase A knock-
out mice, peak LC norepinephrine efflux is higher and
is accompanied by decreased clearance rates and a2
control over release in brain slices (Owesson et al., 2002,
2003). Similar adaptations to vBNST norepinephrine
were found in anesthetized rats following stressors,
as discussed below in Adaptations in Catecholamine
Function.
D. Other Modulators of Catecholamine Release
Terminal catecholamine release can be modulated by
other signaling molecules. For example, acetylcholine’s
actions through cholinergic receptors modulate dopamine
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concentrations dependent on stimulation frequency
(Zhang et al., 2009). In a study designed to mimic the
tonic (,5 Hz) and phasic (20 Hz) firing patterns of
dopamine neurons found in vivo, Zhang et al. (2009)
used slice voltammetry to measure dopamine release
during differing stimulation frequencies. In this work,
blockade of b2-containing nicotinic acetylcholine recep-
tors (nAChRs) predominantly suppressed dopamine
evoked from tonic (,5 Hz) stimulation trains (Zhang
et al., 2009). However, decreased dopamine release
after nAChR blockade was frequency dependent, and
dopamine release increased under nAChR blockade at
frequencies over 10 Hz (Zhang et al., 2009). Acetyl-
choline can also modulate dopamine release indepen-
dent of midbrain dopamine neuron activity, and
optogenetic activation of cholinergic interneurons
alone is sufficient to elicit dopamine release in brain
slices containing the striatum, as well as in intact
animals (Cachope et al., 2012; Threlfell et al., 2012).
Acetylcholine released from cholinergic interneurons
acts directly on dopamine terminals in the NAc to
evoke release that is dependent on b2-containing
nAChRs, and this cholinergic activity does not require
activation of midbrain dopamine neurons (Cachope
et al., 2012; Threlfell et al., 2012). In addition to
optogenetic or electrical stimulations, insulin also
activates cholinergic interneurons to enhance dopa-
mine release in striatal slices (Stouffer et al., 2015).
However, in slices containing the ventral tegmental
area (VTA), insulin instead suppresses somatodendritic
release and enhances dopamine reuptake (Mebel et al.,
2012).
Nitric oxide (NO) donors also modulate dopamine in a
manner dependent on cholinergic activity. Under re-
duced acetylcholine, NOmodulates dopamine release in
slices in a frequency-independent manner and acts
directly on dopamine terminals, in contrast to its
frequency-dependent modulations in the presence of
nicotinic receptor activity (Hartung et al., 2011). We
could find no reports detailing how norepinephrine
release is influenced by other signaling molecules in
slices. Because infusion of NO donors into the BNST
produces anxiety (Faria et al., 2016), and norepineph-
rine in the BNST regulates the stress axis (Forray and
Gysling, 2004), NO donors may potentiate norepineph-
rine release in the BNST to produce elevated stress/
anxiety, but this has not yet been shown. Additionally,
a host of neuropeptides is known to regulate BNST
activity (Kash et al., 2015) and may, in turn, regulate
norepinephrine release. By combining slice voltam-
metry with the diverse toolbox of genetic manipu-
lations, specific cell-type activation, and selective
pharmacology, new modulators of catecholamine re-
lease will be identified that will contribute to a better
understanding of how these neurotransmitters are
regulated and aid in the development of more effective
pharmacotherapies.
III. In Vivo Recordings in Anesthetized Animals
A. Pharmacological Validation
Voltammetric measurements in anesthetized ani-
mals allow for precise measurements of release and
uptake in the intact brain. Because neural activity is
suppressed in anesthetized animals, neurotransmitter
release is typically elicited by stimulating neurons or
their axon bundles directly. Early studies used direct
electrical stimulation, although recent optogenetic strate-
gies provide an opportunity to excite or inhibit discrete
cell types (Witten et al., 2011; McCutcheon et al., 2014).
Dopamine and norepinephrine differ structurally by
only a hydroxyl group, and their voltammograms in
vivo are indistinguishable (Park et al., 2009). Thus, we
have turned to a multistep approach to validate the
origin of the signal at the electrode. First, we limit our
measurements to regions containing predominantly
dopamine or norepinephrine. Tissue homogenate stud-
ies have confirmed that norepinephrine is the primary
catecholamine in the vBNST and the anteroventral
thalamus; thus, our first in vivo norepinephrine mea-
surements were restricted to those regions (Park et al.,
2009). Many dopamine-rich regions lie adjacent to the
vBNST, and, without the visual confirmation of elec-
trode placement afforded by a slice preparation, we
turned to a pharmacological approach to rule out contri-
butions by dopamine (Fig. 2). Voltammetric signals are
only considered noradrenergic if they respond to adren-
ergic agents (e.g., a2 antagonist idazoxan), but not
dopaminergic agents (e.g., D2 antagonist raclopride).
Finally, a constant current is applied to the carbon-fiber
electrode to make a lesion in the brain for subsequent
histologic validation of electrode placement in the tar-
get region.
B. Differential Release of Catecholamines in
Anesthetized Animals
1. Dopamine. Dopamine release is typically evoked
by stimulating neurons in the VTA/substantia nigra
(SN) or the medial forebrain bundle (MFB). The excel-
lent spatial selectivity afforded by microelectrodes al-
lows for characterization of regulation mechanisms in
discrete structures or microdomains of a given region.
By carefully lowering the carbon-fiber and stimulating
electrodes, it is possible to generate a functional map of
the neurons and terminals that support catecholamine
release. Early studies used voltammetry in anes-
thetized rats to reveal an apparent heterogeneity of
release and uptake in compartments of the striatum
and basolateral amygdala (BLA) (May andWightman,
1989; Garris and Wightman, 1994b). Dopamine regu-
lation also differs between the NAc and the olfactory
tubercle (OT) (Wakabayashi et al., 2016). Dopamine
release reaches smaller concentrations in the OT as
compared with the NAc, and DAT inhibition produces
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Fig. 2. Spatially resolved measurements combined with pharmacology ensure either dopamine or norepinephrine measurements. Brain slice, adapted
from the atlas of Paxinos and Watson showing norepinephrine terminals (red) surrounded by dopamine terminals (yellow), highlighting the need for a
small sensor. Boxes show mock electrically stimulated response types to different drugs. Red bar denotes stimulation. In the green box, a pure
dopamine signal increases with D2 antagonism and remains elevated with a2 antagonism; a pure norepinephrine signal does not increase following D2
antagonism and only responds to a2 antagonism. In the red box, a mixed dopamine/norepinephrine signal responds to both D2 and a2 antagonists. ac,
anterior commissure; dBNST, dorsal bed nucleus of the stria terminalis; DS, dorsal striatum; VP, ventral pallidum.
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smaller increases in OT dopamine compared with NAc
(Wakabayashi et al., 2016).
Recent work in our laboratory has used this classic
mapping approach combined with multiple electrodes
and pharmacology to reveal an unexpected population
of dopamine neurons that release dopamine into the
contralateral striatum (Fox et al., 2016a). Stimulations
of the VTA elicit dopamine release in the NAc both
ipsilateral and contralateral to the stimulation, al-
though release is ;20 higher following ipsilateral
versus contralateral VTA stimulations. Contralaterally
projecting dopamine neurons originating from the VTA
are also differentially regulated by D2 receptors be-
cause they are more sensitive to the D2 antagonist
raclopride than ipsilateral VTA projections (Fox et al.,
2016a). Dopamine is also released in the dorsal stria-
tum following stimulations of the contralateral SN. In
contrast to the NAc, dopamine release in the dorsome-
dial striatum exhibits hemispheric equivalence, that is,
dopamine release is of similar magnitude following
ipsilateral or contralateral SN stimulations (Fox et al.,
2016a). Hemispherically equivalent dopamine release
in the dorsomedial striatum is also found after stimu-
lating the ipsilateral or contralateral pedunculopontine
tegmental nucleus (PPTg), an excitatory input to the
SN. Furthermore, hemispherically equivalent release is
accompanied by similar D2 control over contralateral
and ipsilateral SN projections (Fox et al., 2016a). These
findings suggest that differential D2 receptor control
may underlie the differences between contralateral
dopamine release in the NAc and striatum. Although
anatomic (Geisler and Zahm, 2005) and behavioral
(Steinberg et al., 2014) data support cross-hemispheric
dopamine projections, voltammetric measurements
confirm their functional nature and precipitate new
areas of inquiry regarding contralateral catecholamine
projections.
Other work in intact animals has revealed NAc
dopamine release is differentially modulated by a6-
containing nAChRs. Infusion of the a6 nAChR antago-
nist a-conotoxin MII into the VTA decreases evoked
dopamine in the NAc (Wickham et al., 2013). However,
similar a6 antagonism in slice preparations containing
the NAc results in enhanced dopamine release (Exley
et al., 2008). These findings suggest that nAChRs can
modulate dopamine release in a site-dependent manner
and highlight the importance of making measurements
in an intact brain. The high spatial resolution afforded
by microelectrodes combined with site-specific phar-
macological approaches will continue to enable func-
tional characterization of dopaminergic circuits in
intact animals.
2. Norepinephrine. In anesthetized animals, norepi-
nephrine release is typically measured by stimulating
neurons in the nucleus of the solitary tract, or its axon
bundles. Although most in vivo norepinephrine studies
are conducted in the vBNST, both the dorsal BNST and
the NAc shell receive some norepinephrine innervation
in addition to dopamine. Selective pharmacology indi-
cates that norepinephrine in the NAc is restricted to the
more caudal portion of the shell (Park et al., 2010), and
norepinephrine in the dorsal BNST is contained to the
medial portion (Herr et al., 2012). In a study designed to
compare norepinephrine responses between dorsal and
ventral BNST, researchers found norepinephrine re-
lease in the dorsomedial BNST is;50%of vBNST release
(Herr et al., 2012). Accompanying reduced release
amplitudes in the dorsomedial BNST are slower clear-
ance rates and reduced a2 autoreceptor function as
compared with regulation in the vBNST (Herr et al.,
2012).
To directly compare evoked catecholamines, Park
et al. (2011) used a dual-electrode approach to measure
dopamine and norepinephrine release simultaneously
in the NAc and vBNST with stimulations that targeted
both noradrenergic axons and the VTA/SN. As pre-
viously demonstrated in slices, release and uptake of
norepinephrine in the vBNST are slower as compared
with dopamine in the NAc, even with identical stimu-
lation location (Park et al., 2011). The two catechol-
amines are also differentially regulated. Tyrosine
hydroxylase inhibition depletes dopamine release faster
than norepinephrine, and basal levels of dopamine
increasewhenD2 receptors are antagonized and uptake
is blocked with amphetamine (Park et al., 2011). In
contrast, there are no elevations in basal norepineph-
rine in the vBNST following uptake inhibition with
amphetamine and concomitant a2 autoreceptor inhibi-
tion (Park et al., 2011). This contrasting regulation
is also found in studies using more selective uptake
inhibition. When dopamine D2 autoreceptors and
DAT are blocked in anesthetized animals, dopamine
concentrations fluctuate spontaneously in the striatum
(Venton and Wightman, 2007). However, similar block-
ade of noradrenergic a2 autoreceptors andNET does not
elicit spontaneous norepinephrine fluctuations in the
vBNST (Park et al., 2015). Although norepinephrine
and dopamine have similar regulation mechanisms,
they signal in distinct ways when control mechanisms
are blocked. These findings hint at unknown mecha-
nisms controlling norepinephrine release beyond that of
noradrenergic autoreceptors and transporters. Similar
to dopaminergic modulation by nAChRs, norepineph-
rine release is most likely influenced by other recep-
tor types, but further work is needed to identify their
contributions. Additionally, the larger stimulations re-
quired to elicit release of norepinephrine suggest that
norepinephrine is only released endogenously under
extreme physiologic conditions, in stark contrast to
dopamine.
3. Mixed Catecholamines. A few studies have made
measurements in regions with mixed catecholamines,
despite their indistinguishable voltammograms. The
prefrontal cortex (PFC) receives both dopaminergic and
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noradrenergic innervation, and early work shows dopa-
mine is the predominant catecholamine released in the
medial PFC following VTA stimulations (Garris et al.,
1993). This finding was confirmed in a recent report;
however, D2 receptor antagonism paradoxically atten-
uates dopamine release in this region (Shnitko and
Robinson, 2014). Pharmacology in cortical regions must
thus be selected carefully for signal validation, partic-
ularly because NET takes up dopamine in the PFC
(Moron et al., 2002). In future endeavors, selective
stimulation methods, combined with anatomic and
pharmacological validation, will enable additional vol-
tammetric characterization of catecholamine signaling
in regions receiving mixed innervation.
C. Adaptations in Catecholamine Function
Voltammetric measurements in anesthetized ani-
mals allow for researchers to identify how different
manipulations interact with intact circuitry to produce
functional adaptations in catecholamine release. For
example, researchers used anesthetized animals to
determine the role of N-methyl-D-aspartate receptors
(NMDARs) expressed specifically in dopamine neurons
(Zweifel et al., 2009). This study found genetic inacti-
vation ofNMDARs in dopamine neurons disrupts evoked
dopamine release in a stimulation site-dependent man-
ner. Whereas dopamine release is unchanged in NMDAR
knockout mice following MFB stimulations, dopamine
release elicited by the PPTg is blunted as compared with
controls (Zweifel et al., 2009). Without the intact circu-
ity afforded by an anesthetized preparation, the site
specificity of glutamatergic modulation of dopamine
release may not have been uncovered. Another study
found altered dopamine release in mice overexpressing
the catecholamine metabolic enzyme catechol-o-methyl
transferase (Simpson et al., 2014). In mice overexpress-
ing catechol-o-methyl transferase, striatal dopamine re-
lease capacity is increased despite unchanged levels of
tyrosine hydroxylase or DAT (Simpson et al., 2014). It
is clear that measuring the functional consequence
of genetic manipulation on dopamine release provides
more information than markers of dopaminergic activ-
ity alone.
In addition to genetic alteration, recent work in our
laboratory has examined how baseline genetic differ-
ences impact catecholamine regulation mechanisms. In
these studies, norepinephrine release was compared in
the vBNST of Sprague-Dawley (SD), Lewis, andWistar-
Kyoto (WKY) rats (McElligott et al., 2013; Fox et al.,
2015). Whereas release and uptake were similar be-
tween SD and WKY rats (Fox et al., 2015), there were
marked differences in uptake and autoreceptor control
in Lewis rats (McElligott et al., 2013). Although the
amplitude of norepinephrine release was similar in all
three strains, Lewis rats showed slower norepinephrine
uptake rates as compared with SD orWKY rats, despite
no difference in apparent NET expression (McElligott
et al., 2013). Similarly, a2 function, but not expression
was attenuated in Lewis rats, because elevation of
evoked norepinephrine was blunted in Lewis rats after
a2 antagonism with idazoxan as compared with SD rats
(McElligott et al., 2013). Additionally, depletion of LC
norepinephrine with DSP-4 produced adaptations to a2
receptors and uptake in SD, but not WKY rats, without
changing norepinephrine release magnitude (Fox et al.,
2015). These findings underscore the importance of
voltammetric catecholamine measurements in intact
systems, because differential release and uptake most
likely contribute to the phenotypic variations observed
in genetically diverse animal models.
Dysregulations in catecholamine signaling are impli-
cated in the development of addiction and numerous
neuropsychiatric conditions (Koob and Volkow, 2010).
Several studies have used anesthetized preparations to
uncover adaptations to catecholamine circuits following
administration of drugs of abuse. Chronic administra-
tion of cocaine, heroin, or a “speedball” cocktail of the
two produces variable adaptations to NAc dopamine in
rats. In animals with a history of chronic cocaine,
heroin, or speedball self-administration, evoked dopa-
mine is reduced compared with animals receiving a
single drug dose (Pattison et al., 2012). Dopamine re-
uptake rate is also greater in speedball-administering
animals compared with drug-naive animals, or animals
that self-administered cocaine or heroin alone (Pattison
et al., 2012). This hypofunction of the dopamine system
after cocaine self-administration was confirmed in
another recent report (Siciliano et al., 2015b). However,
1-day pretreatment with cocaine does not alter the dopa-
mine response to a subsequent cocaine challenge (Addy
et al., 2010).
Another study examined the effect of repeated co-
caine treatment on dopamine release, and found that
7 days of cocaine exposure instead potentiated the effect
of a cocaine challenge on dopamine signaling in the
NAc. This increase in elevated dopamine after cocaine
was accompanied by an increase in apparent Km of DAT
(Addy et al., 2010). This study appears to contradict
numerous reports describing blunted dopaminergic
responses to cocaine after cocaine self-administration
(Mateo et al., 2005; Ferris et al., 2012; Calipari et al.,
2014a; Siciliano et al., 2015a,b). However, it is impor-
tant to note that Addy et al. (2010) used once per day
experimenter-delivered cocaine (in contrast to the
6-hour self-administration sessions used in Siciliano
et al., 2015b). Furthermore, electrochemical measure-
ments were made after .24 hours of withdrawal in
Addy et al. (2010), as opposed to ;18 hours in Siciliano
et al. (2015b). It is possible that the differences in
dopamine release in response to cocaine challenge
reflect the different dosing regimen between the two
studies, or adaptations to dopamine regulation follow-
ing a longer withdrawal period. In support of the
prolonged cocaine withdrawal hypothesis, Cameron
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et al. (2016) found that after 30 days of forced absti-
nence, a cocaine challenge increased NAc dopamine
release in animals with a history of self-administration.
Future work should address the mechanisms underly-
ing dopaminergic adaptations after variable periods of
cocaine withdrawal because this plasticity appears to be
time-course dependent.
There is some evidence that k opioid receptors may
play a role in differential cocaine-potentiated dopamine
release after withdrawal. The endogenous ligand for k
opioid receptors is dynorphin, which is released in
response to stressful events (Chavkin, 2013), such as
drug withdrawal. The k activation alone inhibits evoked
dopamine in the NAc, and, on a short time scale,
pretreatment with a k agonist attenuates the dopamine
response to cocaine in the NAc (Ehrich et al., 2014).
However, on a longer time scale, pretreatment with a k
agonist increases the cocaine-induced increase in NAc
dopamine (Ehrich et al., 2014), similar to potentiated
dopamine release after.24-hour withdrawal, or 30 days
of forced abstinence (Addy et al., 2010; Cameron et al.,
2016). Further work is needed to determine whether k
opioid receptor activation alone can explain the differ-
ences between these studies (Addy et al., 2010; Siciliano
et al., 2015b; Cameron et al., 2016). Regardless, the time-
course dependence of k opioid modulation of dopamine is
interesting in the context of stress-induced cocaine use. It
is possible that dynorphin released in response to stress
promotes a dysphoric state that drives drug use. On a
short time scale, this stress may decreases cocaine’s
actions on mesolimbic dopamine, resulting in escalation
of drug intake to compensate for cocaine’s attenuated
effect. However, on a longer time scale, k activation may
potentiate cocaine’s effects on dopamine, further driving
its reinforcing properties. Although cocaine increases
extracellular dopamine concentrations, it is clear that
there are other signalingmechanisms outside of elevated
dopamine that drive persistent drug use.
Adaptations to dopamine signaling have also been
studied in anesthetized animals after other drugs of
abuse. An acute dose of ethanol decreases evoked
dopamine and slows clearance in the medial PFC
(Shnitko et al., 2014). Release magnitudes are likewise
suppressed in the medial PFC when ethanol is infused
directly into the VTA (Shnitko et al., 2014), and a
systemic ethanol challenge also reduces NAc dopamine
release (Shnitko et al., 2016). In animals with adoles-
cent alcohol exposure, tonic levels of NAc dopamine are
reduced in adulthood, and these animals exhibit in-
creased risk-taking behavior (Schindler et al., 2016).
Although tonic NAc dopamine is reduced, phasic NAc
dopamine release is increased in animals with ado-
lescent alcohol exposure, in a manner dependent on
stimulation location: PPTg- but not MFB-evoked phasic
dopamine release is increased compared with alcohol-
naive animals (Schindler et al., 2016). In agreement
with this, another study found adolescent alcohol
exposure enhances VTA-stimulated dopamine release
in the NAc, and an ethanol challenge produces larger
increases in stimulated dopamine release compared
with alcohol-naive animals (Shnitko et al., 2016). In-
terestingly, the administration of an allosteric GABAA
agonist attenuates both increased dopamine release
and increased risk-taking behavior in animals with
adolescent alcohol exposure (Schindler et al., 2016).
These findings suggest that there is increased inhibi-
tory tone after alcohol exposure that drives changes in
dopaminergic signaling through a disinhibitory mecha-
nism, which may contribute to the behavioral changes.
Although acute ethanol reduces evoked dopamine in
both the NAc and medial PFC, alcohol exposure in
adolescence clearly leads to dopaminergic plasticity
that may increase the reinforcing properties of alcohol
later in life.
In addition to alcohol, large doses of methamphet-
amine have also been shown to reduce evoked striatal
dopamine and decrease DAT uptake rates (Howard
et al., 2011). These large doses are considered neuro-
toxic and result in decreased striatal DAT levels
(Howard et al., 2013). Pretreatment with neurotoxic
doses of methamphetamine reduces the concentrations
of both pharmacologically induced (Robinson et al.,
2014) and naturally occurring dopamine transients
(Howard et al., 2013). Although drugs of abuse can
increase dopaminergic transmission (Covey et al.,
2014), it is clear that this is dependent on dosing and
prior drug exposure.
Work investigating adaptations to norepinephrine
signaling has been limited, but two recent studies from
our laboratory examined the effects of stress and drug
exposure on norepinephrine release and regulation.
Three days of naloxone-precipitated morphine with-
drawal dysregulates norepinephrine signaling in the
vBNST in a strain-dependent manner (McElligott et al.,
2013; Fox et al., 2015). In morphine-withdrawn SD rats,
a2 receptors become desensitized, norepinephrine clear-
ance rate is slowed, and these animals exhibit increased
anxiety-like behavior (McElligott et al., 2013; Fox et al.,
2015). In morphine-withdrawn WKY rats, norepineph-
rine clearance rate is unchanged, but these animals
exhibit increased anxiety-like behavior and decreased
a2 receptor function (Fox et al., 2015). Lewis rats exhibit
elevated anxiety-like behavior at baseline, and mor-
phine withdrawal does not further elevate anxiety, nor
depress a2 function or norepinephrine clearance in
these animals (McElligott et al., 2013). Furthermore,
following 2 weeks of social isolation stress, stressed SD
rats resemble morphine-dependent rats, that is, ele-
vated anxiety-like behavior, desensitized a2 receptors,
and slow norepinephrine clearance in the vBNST
(McElligott et al., 2013; Fox et al., 2015). In contrast,
WKY rats do not change anxiety-like behavior or
vBNST norepinephrine regulation in response to social
isolation stress (Fox et al., 2015). Similar to drug
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exposure, Lewis rats do not alter noradrenergic syn-
aptic function following social isolation, suggesting
their regulation mechanisms are maximally disrupted
(unpublished data). These findings underscore the
importance of genetic factors in susceptibility to cate-
cholamine dysregulation after stress exposure or drug
withdrawal.
Researchers have also used anesthetized animals to
investigate the mechanisms of nonabused drugs on
catecholamine regulation. For example, the dopamine
precursor, levodopa (L-DOPA), enhances dopamine re-
lease in both dorsal and ventral striatum, but causes a
delayed inhibition of dopamine release in the dorsal
striatum (Harun et al., 2015). L-DOPA also reduces
uptake rates by decreasing Vmax of DAT (Harun et al.,
2015). Because dopamine is the metabolic precursor to
norepinephrine, L-DOPA may also affect norepineph-
rine concentrations, but this area is currently unex-
plored. Noradrenergic deficits are also a key component
in the development of Alzheimer’s disease, and the way
pharmacotherapies alter catecholaminergic function
should be a topic of ongoing investigation. Electro-
chemical measurements in anesthetized animals allow
researchers to examine discrete circuits and how they
become functionally altered after a variety of treat-
ments. Continued efforts should focus on changes in
norepinephrine function in addition to dopamine due to
their different patterns of release and uptake in vivo.
IV. Catecholamine Function in Awake Animals
A. Spontaneous Fluctuations
The first awake-animal FSCV dopamine measure-
ments were conducted nearly 20 years ago, and the
signals that researchers found were closely associated
with a novel stimulus or environment (Garris et al.,
1997; Rebec et al., 1997; Robinson et al., 2001). However,
dopamine concentrations were also found to fluctuate in
the absence of any external stimuli in awake animals
at rest (Robinson et al., 2002) (Table 1). Spontaneous
dopamine fluctuations, or transients, have been mea-
sured in the dorsal striatum, nucleus accumbens, and
olfactory tubercle (Robinson et al., 2002), and they
display heterogeneity in their frequency, amplitude,
and duration in subregions of the NAc (Wightman et al.,
2007). Dopamine transients in the NAc originate from
phasic cell firing in the VTA (Sombers et al., 2009),
are increased by cannabinoid receptor activation (Cheer
et al., 2004), and are the main source of average
extracellular NAc dopamine levels (Owesson-White
et al., 2012). DAT blockade with nomifensine increases
spontaneous and stimuli-related dopamine transients
(RobinsonandWightman, 2004), andacutephenylalanine/
tyrosine depletion reduces the frequency, but not ampli-
tude, of spontaneous transients (Shnitko et al., 2016).
Additionally, cocaine increases the magnitude and dura-
tion of spontaneous dopamine transients in the NAc core
and shell, but increases in dopamine transient frequency
after cocaine are only found in the NAc shell (Aragona
et al., 2008).
Recent work employing a dual-electrode approach
has revealed that, at rest, spontaneous dopamine tran-
sients in the NAc shell synchronize ;75% of the time
between hemispheres (Fox et al., 2016a). Importantly,
FSCV measurements of dopamine transients provide a
clearer picture of dopaminergic activity, as the time
course of dopamine transients as measured by FSCV is
more closely linked with uptake inhibition-induced
stereotypy than microdialysis measurements (Budygin
et al., 2000). In contrast to striatal dopamine, norepi-
nephrine concentrations are not known to fluctuate spon-
taneously in the vBNST of animals at rest (Park et al.,
2012, 2013; Fox et al., 2016b), further illustrating
the differences in endogenous catecholamine signaling
(Table 1).
B. Intracranial Self-Stimulation
Intracranial self-stimulation (ICSS) was first de-
scribed by Olds and Milner (1954), and, through ex-
tensive mapping studies, it was determined that sites
that supported the best self-stimulation were cen-
tered around the medial forebrain bundle, implicating
TABLE 1
Opposing catecholamine responses in awake animals
Upward arrows reflect increases, and downward arrows reflect decreases in
phasic release. Superscripted letters correspond to the following references. The
literature cited in this table is meant to provide notable examples of contrasting
signaling and is by no means comprehensive.
Stimulus NAc Dopamine vBNST Norepinephrine
At rest (transients) Presenta Absentb
ICSS
Stimulation ↑c ↑d
ICSS-predictive cue ↑c No effectd
ICSS-extinction ↓d ↑d
Food reward
Unexpected food ↑e No effectf
Food-predictive cue ↑g Unknown
Food omission ↓h Unknown
Drugs of abuse
Drug exposure ↑i No effectj unknown
Drug-predictive cue ↑k Unknown
Drug withdrawal ↓j ↑j, Unknown
Noxious/Aversive
Quinine ↓l ↑m
Fear cues ↑↓n Unknown
Tail pinch ↑↓o ↑o
aRobinson et al., 2001; Wightman et al., 2007; Sombers et al., 2009.
bPark et al., 2012, 2013; Fox et al., 2016b.
cGarris et al., 1999; Cheer et al., 2007a; Owesson-White et al., 2008.
dPark et al., 2013.
eRoitman et al., 2004, 2008; Cone et al., 2014.
fPark et al., 2012.
gDay et al., 2010; Brown et al., 2011; Cacciapaglia et al., 2012; McCutcheon et al.,
2012; Saddoris et al., 2015b.
hSaddoris et al., 2015a.
iBudygin et al., 2001; Cheer et al., 2004; Heien et al., 2005; Aragona et al., 2008;
Covey et al., 2014; Vander Weele et al., 2014; Fox et al., 2016b.
jFox et al., 2016b.
kPhillips et al., 2003; Stuber et al., 2005; Cameron et al., 2014.
lRoitman et al., 2008; Park et al., 2012; Twining et al., 2015.
mPark et al., 2012.
nBadrinarayan et al., 2012.
oPark et al., 2015.
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catecholamine signaling as a principal mediator of the
behavior. In this paradigm, an animal is trained to
respond instrumentally (e.g., lever press) to deliver an
electrical stimulation to its brain. The presentation of
the lever is traditionally preceded by a cue that predicts
reward availability. Dopamine is released following
direct electrical stimulation of the VTA/SN or MFB,
but, as animals become well trained, the NAc dopamine
release moves to the cue in a time-locked fashion and is
accompanied by decreases in stimulation-evoked dopa-
mine (Table 1) (Owesson-White et al., 2008). To this
end, the dopamine response elicited by a reward-
predicting cue, but not the reward, provides strong
support for dopamine’s involvement in reward predic-
tion error (Schultz, 2013). Furthermore, cue-associated
dopamine release increases when the cue predicts a
greater stimulation magnitude, and this increase is
associated with a decreased latency to lever press for
the stimulation (Beyene et al., 2010).
In early work from Garris et al. (1999), rats were
trained to self-stimulate the VTA in a continuous
manner, that is, the lever was not retracted after each
lever press. These prolonged periods of self-stimulation
sessions diminish the magnitude of NAc dopamine
release, which the authors described as a dissociation
of dopamine release from ICSS.More recent work in our
laboratory has revisited this idea (Rodeberg et al.,
2016). Although dopamine concentrations are markedly
attenuated following continuous ICSS, the disappear-
ance of dopamine during ICSS can instead be attributed
to dopamine concentrations falling below the limit of
detection (Rodeberg et al., 2016). Thus, although pro-
longed periods of stimulation diminish dopamine re-
lease magnitudes, dopamine is still an important
mediator of VTA self-stimulation behavior.
Further work has uncovered how dopamine interacts
with specific postsynaptic receptors in the NAc to drive
ICSS (Owesson-White et al., 2016). In this study,
Owesson-White et al. (2016) employed a multimodal
sensor that combines voltammetric dopamine measure-
ments with single-unit activity. This method allows for
the real-time characterization of dopaminergic modu-
lation of cell firing in awake animals (Takmakov et al.,
2011), and can be paired with iontophoresis to probe
local receptor activity (Belle et al., 2013). In this study,
rats were trained to press a lever for electrical stimu-
lation of the VTA (Owesson-White et al., 2016). Dopa-
mine was released in the NAc following cue presentation
and lever press, and unit activity was associated with
either the cue or the lever press, but not both. For cue-
responsive cells, increased dopamine release occurred
with broad increases in firing rate. For lever press–
responsive cells, activity either increased or decreased,
and the changes in firing rate to the press were shorter
in duration than elevations in dopamine. Locations with-
out changes in unit activity were also without dopa-
mine release; thus, changes in activity could be attributed
to dopamine’s actions at its receptors (Owesson-White
et al., 2016).
To identify the receptor-level mechanisms behind
dopaminergic modulation of cell firing, the authors
coupled iontophoresis barrels to the multimodal sensor
(Owesson-White et al., 2016). Cell firing was altered
following delivery of specific pharmacological agents;
thus, neurons could be chemotyped as containing D1 or
D2 dopamine receptors (Belle et al., 2013). One pop-
ulation of lever press–responsive cells was identified as
D1-containing, and two-thirds of these D1 cells were
excited during the lever press. The remaining lever-
press cells were identified as D2-containing, and 90% of
these cells responded with an inhibition. Remarkably,
when the authors identified the cue-responsive cells,
they were all excitatory and D2-containing. Taken
together, this study reveals dopamine responses to the
cue exclusively activate D2-containing neurons in the
NAc, whereas dopamine’s actions through both D1 and
D2 receptors modulate the activity of lever press–
responsive cells (Owesson-White et al., 2016). The
coupling of iontophoresis with electrochemical and
electrophysiological recordings provides a technical
advantage over previous drug delivery techniques
because large volumes of drugs can disrupt lever
pressing for ICSS (Cheer et al., 2007a). Future work
employing this discrete drug delivery technique will
allow for receptor-level mechanisms to be uncovered in
real time, without necessitating the use of transgenic
animals. Furthermore, this technique may be extended
into regions containing mixed catecholamines for sig-
nal validation prior to making measurements during
behavior.
Typical ICSS stimulations also target noradrenergic
axons, and, in one study, dopamine and norepinephrine
responses were recorded in the dorsolateral and ventral
BNST during ICSS (Park et al., 2013). Both norepi-
nephrine and dopamine were evoked by the electrical
stimulation delivered following the lever press (Table 1)
(Park et al., 2013). Similar to the NAc, cues that predict
lever presentation elicited dopamine release in the
dorsolateral BNST; however, cues did not elicit norepi-
nephrine release in the vBNST even during NET
inhibition (Park et al., 2013). When animals underwent
extinction, that is, a lever press no longer resulted in
electrical stimulation, norepinephrine and dopamine
overflow switched. Whereas norepinephrine was re-
leased in the vBNST at the time of stimulation antic-
ipation, dopamine concentrations in both NAc and
dorsolateral BNST decreased (Park et al., 2013)
(Table 1). Although norepinephrine release is not
elicited by cues predicting ICSS, its release during
extinction may serve as a signal to guide action
selection. When effort no longer results in reward or
positive outcome, norepinephrine signaling may facili-
tate learning about the negative outcome. Indeed,
animals lacking LC norepinephrine lever press longer
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andwithmore vigor during ICSS extinction (Mason and
Iversen, 1979), and LC lesions impair attention (Selden
et al., 1990). Future work should address the involve-
ment of norepinephrine in extinction from other reward
paradigms, which may provide insight into how action
selection is shaped in the context of negative or un-
anticipated outcomes.
C. Natural Rewards
Anumber of studies havemeasured dopamine release
in response to natural rewards, such as food pellets or
sucrose. In general, unexpected delivery of food reward
elicits dopamine release in the NAc, and the magnitude
of dopamine release is greater in animals previously
food-restricted (Roitman et al., 2008; Cone et al., 2014)
(Table 1). Glutamatergic inputs to dopamine neurons
are important for dopamine release in response to food,
because mice lacking NMDARs in dopamine neurons
exhibit reduced dopamine release in the NAc after
unexpected food delivery (Parker et al., 2010). Addi-
tionally, dopamine release to unexpected food is poten-
tiated by infusions of grehlin in the lateral ventricle or
intra-VTA orexin-A (Cone et al., 2014).
Dietary changes can also cause adaptations in dopa-
minergic signaling, and a prolonged high-fat diet reduces
uptake without altering DAT gene expression (Cone
et al., 2013). Diet can also alter insulin sensitivity, and
insulin-deficient rats have reduced DAT surface expres-
sion and dopamine uptake (Williams et al., 2007). Insulin
can suppress somatodendritic dopamine concentrations
in the VTA through increased uptake (Mebel et al.,
2012); however, in the NAc, insulin signaling enhances
dopamine release by exciting cholinergic interneurons
(Stouffer et al., 2015). Importantly, the effect of insulin
on striatal dopamine release is diet-dependent: rats fed
an obesogenic diet exhibit a complete loss of insulin-
potentiated dopamine release (Stouffer et al., 2015). It is
clear that diet and insulin can alter dopaminergic func-
tion, but further work is needed to more precisely eluci-
date the mechanism by which diet-altered dopamine
function contributes to maladaptive eating behavior.
In contrast to dopamine, little is known regarding
norepinephrine signaling during caloric rewards or
changes to diet, which is of particular interest given
norepinephrine’s involvement in anorexia and feeding
behavior (Janhunen et al., 2013; Nedelescu et al., 2016).
Only one study examined norepinephrine release during
food administration, and found unexpected sucrose de-
livery does not elicit vBNST norepinephrine release
(Park et al., 2012) (Table 1). Norepinephrine release in
the vBNST may instead coincide with food omission as
it is during omission of ICSS reward (Park et al., 2013);
however, this remains to be shown. Norepinephrine
release during food omission has interesting implica-
tions in the context of feeding behavior. Because
vBNST norepinephrine can influence the hypothalamic–
pituitary–adrenal axis (Forray and Gysling, 2004), it may
engage the brain’s stress centers to suppress feeding and
promote anorexia. Future work should address the role of
norepinephrine signaling during delivery and omission of
high-calorie foods to determine how it contributes to
dysregulated food consumption.
Food-predictive cues also elicit dopamine release in
the NAc (Roitman et al., 2004) and dorsolateral stria-
tum (Shnitko and Robinson, 2015). In the NAc, sucrose-
predictive cues evoke greater dopamine release than
those that predict saccharin (McCutcheon et al., 2012)
(Table 1). There is some evidence that inputs from the
BLAmodulate NAc dopamine release to food-predictive
cues, because inactivation of the BLA with baclofen/
muscimol attenuates NAc dopamine evoked by sucrose-
paired cues (Jones et al., 2010). Interestingly, this
manipulation does not diminish VTA-stimulated dopa-
mine release in the NAc, and suggests the glutamater-
gic inputs from the BLA modulate NAc dopamine
through a terminally mediated mechanism (Jones
et al., 2010). In support of glutamatergic influence over
NAc dopamine responses, mice lacking NMDARs re-
lease smaller concentrations of dopamine in the NAc
during delivery of a food reward (Parker et al., 2010).
Dopamine released in response to a food-predictive cue
selectively modulates cells in the NAc that are excited
during the cue, but not those that are inhibited during
the cue (Cacciapaglia et al., 2011). Additionally, dopa-
mine responses vary based on NAc subregion; although
cue-evoked dopamine is observed in both NAc core and
shell, it is of greatermagnitude and duration in the shell
as compared with the core (Cacciapaglia et al., 2012).
When rats must press one lever to extend a second lever
for sucrose delivery, dopamine responses also vary
between the NAc core and shell. In the core, dopamine
release is greatest after presentation of the first lever, or
the “seeking lever,” and less for subsequent presenta-
tion of the “taking lever” and reward delivery. In the
shell, dopamine release is robust to both levers as well
as to reward delivery (Saddoris et al., 2015a).
When animals are asked to choose between immedi-
ate and delayed food reward, dopamine responses in the
shell scale with the interval between cue and reward
delivery, and with an animal’s preferred reward, that is,
dopamine release is greater when the interval between
cue and reward is shorter, and is greater during delivery
of an animal’s preferred reward (Day et al., 2010;
Sugam et al., 2012; Saddoris et al., 2015b). Interest-
ingly, optogenetic enhancement of dopamine release in
the NAc during the cue alters the decisions rats make
regarding which lever to press for varying reward
magnitude, and they alter choice based on delay, but
not reward magnitude (Saddoris et al., 2015b). Norepi-
nephrine may be released in the vBNST during pre-
sentation of a lesser-magnitude reward than anticipated
by the animal, but no studies have investigated norepi-
nephrine signaling in paradigms involving different food
reward magnitude.
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Dopamine release is also elicited during delivery of a
noncaloric reward. In sodium-depleted animals, NAc
dopamine signaling increases when animals are given a
salt solution. Over time, dopamine release moves to the
salt-predictive cue in sodium-depleted rats (Cone et al.,
2016). We could find no similar studies of phasic
norepinephrine response to noncaloric reward.
D. Aversion
A number of studies have examined the effects of
aversive stimuli on dopaminergic transmission. Sys-
temic delivery of the aversive agent lithium chloride
blunts phasic dopamine release in theNAc (Fortin et al.,
2016), and oral administration of the aversive tastant
quinine suppresses dopamine release in the NAc
(Roitman et al., 2008) and dorsolateral BNST (Park
et al., 2012). Quinine reduces dopamine tone in the
NAc by reducing release frequency and is dependent on
corticotropin-releasing factor (CRF) signaling (Twining
et al., 2015). Blocking CRF receptors in the VTA blocks
the inhibitory effect of quinine on NAc dopamine,
suggesting that CRF release during aversive stimuli
can act directly on VTA neurons to suppress NAc
dopamine release (Twining et al., 2015). During quinine
delivery, decreased dopamine in the NAc is accompa-
nied by increased vBNST norepinephrine (Park et al.,
2012). This reciprocal catecholamine signaling during
negative stimuli was also found in a study examining
the noxious stimulus of a tail pinch. The predominant
response during tail-pinch delivery is a suppression of
dopamine overflow in the NAc, whereas the same stim-
ulus elicits norepinephrine release in the vBNST (Park
et al., 2015). Although the tail-pinch study was con-
ducted in anesthetized animals, one might suspect that
norepinephrine overflow increases in awake animals dur-
ing delivery of a noxious stimulus such as a foot shock.
Indeed, markers of noradrenergic activity increase fol-
lowing foot shock (Rassnick et al., 1998; Passerin et al.,
2000).
Due to electrical interference, it is difficult to make
electrochemical measurements of catecholamine re-
lease during delivery of a foot shock. However, recent
work has focused on contrasting dopamine signaling in
the NAc during fear-predictive cues (Badrinarayan
et al., 2012). Cues that predict foot shock decrease
dopaminergic transmission in the NAc core by decreas-
ing the probability of dopamine release. In the NAc
shell, the same cues elicit increases in dopaminergic
transmission by enhancing the amplitude of dopamine
release (Badrinarayan et al., 2012). However, neither
increases nor decreases in NAc dopamine were strictly
associated with freezing behavior elicited by the fear-
predictive cue (Badrinarayan et al., 2012).We could find
no similar studies on phasic norepinephrine responses
during fear-predictive cues. Norepinephrine may be
released in the vBNST during a cue that predicts foot
shock, as it is during the delivery of aversive quinine
(Park et al., 2012), or during a tail pinch (Park et al.,
2015). However, because no work has found norepi-
nephrine responses to cues in general, further work is
needed to investigate this possibility.
E. Social Interaction
Social interactions also elicit phasic dopamine re-
sponses, and the introduction of an unfamiliar rat or
conspecific increases the frequency of dopamine tran-
sients (Robinson et al., 2002). Dopamine is also released
in the NAc in response to prosocial ultrasonic vocali-
zations (Willuhn et al., 2014). However, increased
dopamine release to both prosocial vocalizations and
conspecific interaction declines rapidly following ha-
bituation (Robinson et al., 2002; Willuhn et al., 2014).
NAc dopamine is also modulated by reward delivery to
another rat, as stronger dopamine release is measured
during conspecific reward receipt versus an empty box.
Similar to other prosocial interactions, this response
attenuates, and even becomes reversed in repeated
trials, with reductions in dopamine during conspecific
reward delivery (Kashtelyan et al., 2014).
In rats subjected to social defeat stress, interaction
with an aggressive rat increases burst firing in the VTA
and elevates the frequency of NAc dopamine transients
(Anstrom et al., 2009). However, changes in norepi-
nephrine signaling during an aggressive encounter
have not been studied. Social defeat stress increases
norepinephrine synthesis and NET expression in the
LC (Chen et al., 2012; Fan et al., 2013), suggesting
negative social interaction may alter norepinephrine
release. Furthermore, when Long Evans rats are sub-
jected to social defeat stress, some rats become aggres-
sive. These aggressive rats have increased anxiety-like
behavior, exhibit decreased latency to attack, and have
increased amygdalar norepinephrine content as com-
pared with nonaggressors (Patki et al., 2015). Given
that norepinephrine influences the hypothalamic-
pituitary-adrenal axis, it is tempting to hypothesize
norepinephrine is released in the vBNST during an
animal’s decision to fight or flee during aggressive social
interactions, and this should be a topic of future
investigation.
F. Drugs of Abuse
1. Psychostimulants. Drugs of abuse have variable
actions on catecholamine neurons, and those that in-
terfere with reuptake (e.g., cocaine, psychostimulants)
are traditionally classified as either blockers or releas-
ers. Both categories can suppress firing rates through
global elevation of dopamine and subsequent activation
of D2 autoreceptors, although this effect varies (Shi
et al., 2000, 2004; Koulchitsky et al., 2012). Blockers,
such as cocaine, bind the transporter and allosterically
inhibit reuptake (Torres et al., 2003), whereas releasers,
such as amphetamine, reverse the transporter and
release dopamine in an action-potential–independent
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manner (Sulzer, 2011). However, recent work challenges
the action-potential independence of amphetamine-
evoked dopamine release. Abolishing cell firing in do-
pamine neurons also abolishes amphetamine-elicited
dopamine transients, suggesting that, in awake animals,
amphetamine exerts its effects via an action-potential–
dependent manner (Covey et al., 2016). A large number
of studies have examined the effects of psychostimulants
on spontaneous dopamine transients. To avoid redundant
coverage, we direct the reader to a recent review (Covey
et al., 2014).
2. Cannabanoids. Emerging evidence supports can-
nabinoid modulation of dopamine signaling and drug
reward (Cheer et al., 2007b; Loewinger et al., 2012;
Oleson et al., 2012; Hernandez et al., 2014), and
cannabinoid’s effects on the dopaminergic system have
been recently reviewed in detail (Oleson and Cheer,
2012; Covey et al., 2015). Despite reports that cannabi-
noids increase LC norepinephrine activity (Oropeza
et al., 2005; Page et al., 2007), how cannabinoid receptor
activation influences phasic norepinephrine release has
not been investigated.
3. Alcohol. Electrophysiological data show that eth-
anol stimulates dopaminergic transmission (Brodie
et al., 1999), and tonic activation of VTA dopamine
neurons suppresses voluntary alcohol drinking by
elevating basal dopamine efflux (Bass et al., 2013).
However, there is disparity in alcohol’s effects on
neurochemistry. Microdialysis data support a biphasic
dopaminergic response, in which low doses produce
increases in NAc dopamine (Yoshimoto et al., 1992) and
decreases at higher doses (Blanchard et al., 1993). As
measured by FSCV, acute ethanol dose-dependently
decreases evoked dopamine in the dorsal striatum
(Budygin et al., 2001), but there is an apparent hetero-
geneity of dopamine response in the NAc. In some
recording locations, ethanol increases dopamine tran-
sient frequency, whereas in some the frequency is
decreased or even unaffected (Robinson et al., 2009).
Interestingly, cues that predict a sweetened ethanol
reward are time locked to dopamine release in the
dorsolateral striatum and NAc, but not in the dorsome-
dial striatum (Shnitko and Robinson, 2015). Although
alcohol-predictive cues elicit dopamine release, the
amplitude of release does not differ between rats
consuming sweetened alcohol versus those consuming
the sweetened solution alone (Shnitko and Robinson,
2015). This apparent heterogeneity in dopamine re-
sponse to ethanol should be addressed because alcohol
exposure has circuit-specific effects on dopaminergic
transmission (Schindler et al., 2016). Although ethanol
can enhance stimulated dopamine, its effects on endog-
enous dopamine release are conflicting.
It is currently unknown how ethanol impacts phasic
norepinephrine release. Onemicrodialysis study showed
that ethanol dose-dependently increases basal NAc nor-
epinephrine in animals reared in social isolation, but
not those reared in group housing (Karkhanis et al.,
2014). Future work should address alcohol’s effect on
phasic norepinephrine signaling, particularly in the
BNST, because the BNST can modulate ethanol-
seeking behavior (Pina et al., 2015) and is an important
structure for the development of alcohol use disorders
(Kash, 2012).
4. Opiates. In addition to alcohol, recent work has
examined the effect of an acute i.v. delivery of opiates on
catecholamine release. In one study, researchers de-
livered the opiates oxycodone and morphine to freely
moving rats (Vander Weele et al., 2014). Intravenous
oxycodone increases dopamine transient frequency and
magnitude in the NAc for ;1 hour; however, i.v.
morphine produces a much shorter (;1 minute) in-
crease in phasic dopamine transmission (Vander Weele
et al., 2014). In our laboratory, we extended this work to
determine the impact of drug withdrawal in addition to
drug exposure on dopamine release. In contrast to the
previous report, s.c. administration of morphine pro-
duces a persistent (.1 hour) increase in dopamine
transient frequency; however, the average magnitude
of dopamine transients is similar between animals
given morphine or saline (Fox et al., 2016b). This
difference may reflect the differential time course of
drug delivery between the two studies (Vander Weele
et al., 2014; Fox et al., 2016b). Interestingly, when
animals undergo naloxone-precipitated withdrawal,
dopaminergic transmission decreases in the NAc (Fox
et al., 2016b). In morphine-withdrawn animals, nalox-
one treatment reduces dopamine transient frequency
back to baseline or saline conditions. Furthermore,
naloxone decreases the average concentration per tran-
sient only in animals undergoing morphine withdrawal
(Fox et al., 2016b). However, a single morphine with-
drawal episode is insufficient to elicit persistent ad-
aptations in dopaminergic signaling because after
treatment, electrically evoked dopamine concentra-
tions reach similar amplitudes in animals treated with
naloxone after either saline or morphine (Fox et al.,
2016b). Thus, the decreases in dopaminergic trans-
mission reflect alterations of dopamine signaling spe-
cifically during the withdrawal period.
In this study, we also examined norepinephrine re-
sponses in the vBNST during morphine and precipi-
tated withdrawal (Fox et al., 2016b). In contrast to
NAc dopamine, morphine exposure does not elicit nor-
epinephrine responses in the vBNST. However, robust
norepinephrine release events occur during precipi-
tated withdrawal that coincide with specific somatic
withdrawal behaviors (Fox et al., 2016b). Interestingly,
norepinephrine release during drug withdrawal per-
sists for 10 seconds, in contrast to the brief time course
(;1 second) of spontaneous dopamine transients. These
persistent norepinephrine elevations during with-
drawal occur in a manner similar to norepinephrine
released during ICSS extinction or quinine infusions
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(Park et al., 2012, 2013). Furthermore, a single with-
drawal episode is sufficient to reduce evoked norepi-
nephrine in withdrawn animals (Fox et al., 2016b),
further highlighting the contrast between dopaminergic
and noradrenergic signaling. Importantly, this reduc-
tion in releasable norepinephrine, but not dopamine,
is in agreement with tissue content in the NAc and
vBNST after repeated episodes of opiate withdrawal
(McElligott et al., 2013). Together with the opposing
responses highlighted in Table 1, opposing dopamine
and norepinephrine signaling during drug exposure and
withdrawal support reciprocal roles for catecholamines
during appetitive and aversive stimuli.
G. Norepinephrine–Dopamine Interactions
Due to the opposing nature of NAc dopamine and
BNST norepinephrine, it is tempting to hypothesize
that these reciprocal responses reflect feedback be-
tween the two catecholaminergic systems, and that
norepinephrine release may influence the reduction of
dopaminergic transmission during aversive stimuli.
Indeed, glutamatergic inputs from the vBNST exert
excitatory influence over VTA dopamine neurons
(Georges and Aston-Jones, 2002), and norepinephrine’s
actions through a2A receptors decrease excitatory trans-
mission in the vBNST (Egli et al., 2005). Norepineph-
rine can also act through b receptors to increase GABAA
inhibition of VTA-projecting BNST neurons (Dumont
and Williams, 2004), leading to increased inhibition of
the VTA. In further support for noradrenergic modula-
tion of dopamine transient concentrations, elevation of
norepinephrine with systemic a2 antagonism sup-
presses the magnitude of spontaneous dopamine tran-
sient concentrations in the NAc (Fox et al., 2016b). The
reciprocal actions of dopamine and norepinephrine
during drug exposure and withdrawal (Fox et al., 2016b),
reward-learning and extinction (Park et al., 2013), and
appetitive and aversive tastants (Park et al., 2012)may be
generalized to other paradigms; however, additional work
is needed. Futurework should address how these opposing
responses develop longitudinally to shape learning about
rewarding and aversive stimuli.
V. Clinical Implications
Voltammetric catecholamine measurements in mod-
els of human disease have provided new insights into
their pathogenesis. To model Parkinson’s disease, re-
searchers have turned to animals that express the
mutant proteins found in human patients to uncover
how these mutations lead to catecholaminergic deficits.
For example, researchers expressed mutant human
leucine-rich repeat kinase 2 in rats and found impaired
striatal dopamine release. The adaptations to circuit
function appear in the absence of neurodegeneration,
and suggest that dopaminergic dysfunction might pre-
cede measureable markers of neurodegeneration and
cell death (Sloan et al., 2016). In another study, expres-
sion of mutant a-synuclein in tyrosine–hydroxylase
neurons produces differential catecholamine deficits
that are regionally specific: evoked dopamine is re-
duced in the dorsal striatum, but not in the NAc, and
vBNST norepinephrine release is unchanged (Taylor
et al., 2014). These genetic manipulations afford
ways to test early circuit function, and might become
a useful preclinical model for testing Parkinson’s
therapeutics.
Researchers have also used voltammetry to investi-
gate aberrant dopamine signaling in Angelman syn-
drome. Angelman syndrome is a neurodevelopmental
disorder characterized by ataxic movements, develop-
mental delay, and excessive exuberance (Williams,
2010). Patients with Angelman syndrome lack ubiquitin
ligase E3A (UBE3A), due to mutations or deletions of
the maternal allele UBE3A, and recent work has used
mice lacking maternal UBE3A to model the syndrome
(Riday et al., 2012; Berrios et al., 2016). Mice lacking
maternal UBE3A are more sensitive to VTA self-
stimulation; that is, the mice acquire robust self-
stimulation behavior to lower electrical stimulation
currents (Riday et al., 2012), and deliver more optoge-
netic self-stimulations as compared with controls
(Berrios et al., 2016). Despite the behavioral similarities
between these two studies, they are in apparent con-
trast with one another with respect to changes in
dopamine signaling. Riday et al. (2012) found differen-
tially altered dopamine signaling in UBE3A-deficient
mice without adaptations to the number of dopaminer-
gic cells: whereas NAc dopamine release is increased in
these mice, nigrostriatal dopamine release is attenu-
ated. In contrast, Berrios et al. (2016) used optogenetics
to elicit dopamine release in brain slices containing the
NAc, and found no differences in dopamine release
magnitude between UBE3A-deficient mice or their
controls. However, there are important methodological
differences that may contribute to the apparent differ-
ences in dopamine release between the two studies.
First, direct depolarization of dopamine terminals in a
brain slice is not necessarily indicative of themagnitude
of dopamine release in an intact brain. Second, elec-
trical stimulations do not provide the cell-type specific-
ity of optogenetic approaches. Third, adaptations in
afferent, nondopaminergic neurons may facilitate dys-
regulated signaling that may not be apparent in a slice
preparation. Moving forward, we need to consider the
evidence from both slice and intact animal preparations
to integrate how circuit function becomes disrupted in
disease models.
Recent advances have enabled researchers to also
conduct electrochemical measurements in humans in
parallel with deep brain stimulation probes. Human
recordings typically employ a fused-silica microelec-
trode assembly that houses reference and recording
electrodes and is positioned within or nearby deep brain
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stimulation probes. In the first human recordings,
striatal dopamine fluctuations were measured during
a decision-making task (Kishida et al., 2011). More
recent work asked how dopamine encodes reward pre-
diction errors in Parkinson’s patients (Kishida et al.,
2016). Although this study found dopamine integrates
reward prediction error with counterfactual prediction
error, it is difficult to determine whether this is a
normal property of dopamine neurons, given the rela-
tively low dopamine concentrations and possible ad-
aptations following pharmacological intervention in
Parkinson’s patients. Human measurements are fur-
ther complicated by the calibration methodology often
employed. Although standardized training sets for
principal component analysis may predict the identity
of a given analyte (e.g., dopamine), they are notoriously
poor at concentration prediction, which may lead to
inappropriate interpretation of the data (Johnson et al.,
2016). Nevertheless, information gleaned from preclin-
ical disease models with recordings in humans will
provide newmechanistic insight for the progression and
treatment of neurodegenerative diseases.
VI. Summary
Superficially, dopaminergic and noradrenergic sig-
naling are similar. Both catecholamines are released
from comparably sized vesicles (Bergquist and Ludwig,
2008; Papke et al., 2012) and are taken up by neuronal
transporters, and their release is governed by autore-
ceptors that operate on similar time courses (Palij and
Stamford, 1993; Trendelenburg et al., 2001; Phillips
et al., 2002). Despite strikingly similar mechanisms in
place to control their extracellular concentrations,
voltammetric measurements have uncovered contrast-
ing release and uptake profiles for the two catechol-
amines. Dopamine is released faster, reaches higher
concentrations, and is cleared from the extracellular
space more rapidly as compared with norepinephrine
(Garris and Wightman, 1995). These distinct release
profiles were first appreciated in brain slices, where
striatal dopamine and BNST norepinephrine release
had differential dependence on stimulation intensity
(Kennedy et al., 1992; Miles et al., 2002). Dopamine and
norepinephrine release are similarly divergent in anes-
thetized animals, where identical stimulations produce
markedly different concentrations of the two catechol-
amines (Park et al., 2011). Brain slice measurements
revealed that dopamine reuptake rate is faster than
that of norepinephrine, and DAT appears to play a
stronger role in dopamine clearance compared with
NET’s role in norepinephrine clearance (Jones et al.,
1998; Xu et al., 2000; Miles et al., 2002). In anesthetized
animals, clearance rates for dopamine and norepineph-
rine are similarly divergent (Park et al., 2011), and
simultaneous blockade of DAT and dopamine D2 auto-
receptors elicits spontaneous dopamine fluctuations in
the striatum (Venton and Wightman, 2007). This is in
contrast to simultaneous NET inhibition and adrener-
gic a2 antagonism, which does not produce spontaneous
norepinephrine release in the vBNST of anesthetized
animals (Park et al., 2011, 2015). Despite having
similar mechanisms in place to control release and
uptake, dopamine and norepinephrine signal in mark-
edly different ways.
Contrasting catecholamine signaling has also been
described in awake and behaving animals. Dopamine
concentrations fluctuate spontaneously in the absence
of overt stimuli, whereas norepinephrine concentra-
tions do not (Robinson et al., 2002; Sombers et al.,
2009; Park et al., 2012; Fox et al., 2016b). In awake
animals, the time course of dopamine release is more
rapid than vBNST norepinephrine, with norepineph-
rine release persisting for 10 seconds compared with
;1-second dopamine fluctuations (Park et al., 2012,
2013; Fox et al., 2016b). Furthermore, current evidence
suggests that striatal dopamine and vBNST norepi-
nephrine signal in opposition of each other during
appetitive and aversive stimuli (Table 1). Whereas
dopamine is released during presentation of reward-
predicting cues, norepinephrine is instead released
during reward omission (Park et al., 2013). Dopaminer-
gic transmission typically increases during a positive
stimulus, whereas increased noradrenergic transmis-
sion is associated with a negative stimulus (Park et al.,
2012). Drugs of abuse increase the frequency of dopa-
mine transients, in contrast to norepinephrine released
during drug withdrawal (Fox et al., 2016b). However,
due to the limited number of phasic norepinephrine
measurements, it is impossible to make definitive
claims about the roles of dopamine and norepinephrine
in shaping behavior. Although there is strong evidence
in support of reciprocal catecholamine signaling during
positive and negative stimuli, some reports show dopa-
mine release in response to aversive stimuli (Anstrom
et al., 2009; Badrinarayan et al., 2012). There may be a
similarly unexpected role for phasic norepinephrine
during rewarding stimuli, but further work is needed
to examine this possibility.
Great strides have been made in understanding the
dynamic processes controlling release and uptake of
catecholamines, but there are still unresolved ques-
tions. Notably, contrasting regulation of dopamine and
norepinephrine has been described in regions receiving
solely dopaminergic or noradrenergic innervation, yet it
is unknown whether this pattern is maintained in
regions receiving mixed catecholamine innervation.
Due to the indistinguishable voltammograms of dopa-
mine and norepinephrine, it has been difficult to make
voltammetric measurements in regions receivingmixed
inputs. However, the application of more selective
stimulation methods, combined with pharmacological
signal validation, should enable voltammetric charac-
terization of catecholamine signaling throughout the
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brain. The contrasting regulation of dopamine and
norepinephrine, combined with their opposing nature
during rewarding and aversive stimuli, may not hold
true in all brain regions or behavioral paradigms, and
should be a topic of ongoing investigations.
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